A specific minimum viral load of HIV is required to establish infection
the verdict
INSUFFICIENT LEANING
refutedsupported
the weight of evidence
2 sources for · 0 against
Available evidence discusses viral particle transmission dynamics and detection limits, but does not provide definitive proof that a specific minimum viral load is required to establish infection.
<h4>Background</h4> HIV transmission is characterised by a low per-act probability, a relatively high proportion of multiple variant transmission events, and a plateauing of transmission risk at high viral loads. No existing mechanistic model can simultaneously recapitulate all of these observations, thereby limiting our ability to predict unobserved transmission phenomena and evaluate prevention strategies. <h4>Methods</h4> We developed a suite of mathematical models that encode an empirically plausible set of transmission mechanisms and then fit these models within a Bayesian framework to available epidemiological data to identify which set of mechanisms are sufficient to recapitulate the data. Following formal model comparison, we embedded the best-fit model into a phylodynamic framework and calibrated it using Approximate Bayesian Computation, to assess whether phylogenetic trees from individual transmission pairs were both consistent with the model and informative. Finally, we further validated our most likely model against two large prospective studies (PARTNER1 and STEP). <h4>Results</h4> Our calibrated model predicts that for each systemic infection, approximately four to five transient infections occur—exposure events in which viral replication occurs but is stochastically extinguished—consistent with indirect empirical evidence from the STEP vaccine trial. The model predicts a transmission rate of fewer than 0.05 systemic infections per 100 couple-years follow up from individuals with undetectable viral load, providing a mechanistic basis for the negligible risk observed in the PART-NER1 study. The model also predicts a strong link between the number of viral particles transmitted and the number of variants establishing infection, modulated by the transmitter’s infection stage. Recalibrating for men who have sex with men indicated that higher transmission rates in this population are explained by a single parameter: a greater probability of permissive c
SinceΘis uniform, the probability that the transmitter is in stages ∈ {E, A, L}is:
Pr(S = s|V = v) = τs
τE +τ A(vA) +τ L
.(4)
2.2 Intermittent susceptibility model
In the intermittent susceptibility model, HIV infection can only occur during a small frac-
tion of sexual exposures—specifically those that occur when conditions are permissive for
transmission. Our intermittent susceptibility model follows the same structure as described
elsewhere [7], with two modifications: first, viral loads vary between individuals in the pop-
ulation in all infection stages, consistent with epidemiological data [31, 32]. Second, for
mathematical tractability, we approximate the number of virions transmitted to the exposed
partner using a Poisson distribution (rather than a binomial distribution) because the viral
load in the genital mucosa,v, is large and the per-virion acquisition probability,p, is small.
In this model, the probability thatN1 virions establish infection during a single
bility combined with infrequent permissive conditions for infection, likely reflecting stringent
transmission barriers that fluctuate through time. Second, the relatively high probability
of multiple founder variants was attributed to relaxed bottlenecks during these rare per-
missive exposures allowing multiple virions to establish infection simultaneously. Third, the
plateauing of transmission rates at high viral loads was explained by target cell limitation
at the infection site. Fourth, stage-specific differences in both transmission probability and
the frequency of multiple founder variants were attributed to variations in the probabil-
ity that infected cells establish systemic infection. Beyond reconciling these observations,
the calibrated model yields novel predictions: transient infections occur approximately five
times more frequently than systemic infections, viral suppression reduces transmission risk
by several hundredfold, and higher transmission rates in MSM populations are primarily
explained by a greater probability of permissive conditions for infection, that typically occur
infrequently.
To our knowledge, this is the first model to reconcile all these key epidemiological obser-
vations, and it yields additional insights into HIV transmission. The model predicts a close
association between a transmitter’s viral load and the number of virions infecting exposed
partners, with the transmitter’s infection stage influencing the number of transmitted vari-
ants. These patterns are broadly consistent with previous theoretical predictions [7], with
two notable differences: first, our model permits a wider range of particle counts to cross the
transmission barrier, reflecting a trade-off between particle counts and the per-cell establish-
ment probability; second, during early infection, our model predicts a higher frequency of
two to three founding variants [7], a consequence of fitting to the elevated relative hazard of
multiple founders observed at this stage.
These findings offer a mechanistic interpretation of stage-specific transmission risk. The
probability that an infected cell establishes systemic infection peaks during early infection,
aligning with clinical observations that transmission risk during this stage exceeds what
would be expected from elevated viral load alone [40]. This elevated establishment proba-
bility may reflect the transmission of highly infectious founder-like variants that are subse-
quently lost through immune-driven evolution and antibody neutralisation [41–43]. Consis-
tent with this, transmitters in the asymptomatic stage showed markedly lower per-cell estab-
19
. CC-BY 4.0 International licenseIt is made available under a
is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted March 23, 2026. ; https://doi.org/10.64898/2026.03.20.26348904doi: medRxiv preprint
polymerase chain reaction (PCR) is a laboratory method widely used to amplify copies of specific DNA sequences rapidly, to enable detailed study. PCR was
The polymerase chain reaction (PCR) is a laboratory method widely used to amplify copies of specific DNA sequences rapidly, to enable detailed study. PCR was invented in 1983 by American biochemist Kary Mullis at Cetus Corporation. Mullis and biochemist Michael Smith, who had developed other essential ways of manipulating DNA, were jointly awarded the Nobel Prize in Chemistry in 1993.
PCR is funda
The human immunodeficiency virus (or HIV), is a difficult target to find and eradicate. The earliest tests for infection relied on the presence of antibodies to the virus circulating in the bloodstream. However, antibodies don't appear until many weeks after infection, maternal antibodies mask the infection of a newborn, and therapeutic agents to fight the infection don't affect the antibodies. PCR tests have been developed that can detect as little as one viral genome among the DNA of over 50,000 host cells. Infections can be detected earlier, donated blood can be screened directly for the virus, newborns can be immediately tested for infection, and the effects of antiviral treatments can be quantified.
Some disease organisms, such as that for tuberculosis, are difficult to sample from patients and slow to be grown in the laboratory. PCR-based tests have allowed detection of small numbers of disease organisms (both live or dead), in convenient samples. Detailed genetic analysis can also be used to detect antibiotic resistance, allowing immediate and effective therapy. The effects of therapy can also be immediately evaluated.
The spread of a disease organism through populations of domestic or wild animals can be monitored by PCR testing. In many cases, the appearance of new virulent sub-types can be detected and monitored. The sub-types of an organism that were responsible for earlier epidemics can also be determined by PCR analysis.
Viral DNA can be detected by PCR. The primers used must be specific to the targeted sequences in the DNA of a virus, and PCR can be used for diagnostic analyses or DNA sequencing of the viral genome. The high sensitivity of PCR permits virus detection soon after infection and even before the onset of disease. Such early detection may give physicians a significant lead time in treatment. The amount of virus ("viral load") in a patient can also be quantified by PCR-based DNA quantitation techniques (see below). A variant of PCR (RT-PCR) is used for detecting viral RNA rather than DNA: in this test the enzyme reverse transcriptase is used to generate a DNA sequence which matches the viral RNA; this DNA is then amplified as per the…
Everything we examined (2)
This check searched the claim as stated. It did not run a separate search for evidence against it.